Breaking News Instant updates and real-time market news.

CYNA

Cynapsus Therapeutics

$40.45

0.05 (0.12%)

16:04
10/13/16
10/13
16:04
10/13/16
16:04

Cynapsus holders approve plan of arrangement with Sunovion Pharmaceuticals

Cynapsus Therapeutics is pleased to announce that at its special meeting of shareholders and warrantholders held earlier today, Securityholders approved the special resolution authorizing the previously announced plan of arrangement with Sunovion Pharmaceuticals. Pursuant to the terms of the Arrangement, the Purchaser will acquire all of the outstanding (i) common shares of Cynapsus for US$40.50 cash per common share and (ii) warrants of Cynapsus for US$40.50 cash per warrant minus the exercise price of each warrant. As announced on August 31, the transaction values Cynapsus at approximately US$624 million. The Special Resolution was approved by approximately 99.97% of the common shares and warrants, voting together as one class, voted in person or represented by proxy at the Meeting, as well as by a "majority of the minority" as required pursuant to Multilateral Instrument 61-101. The implementation of the Arrangement remains subject to the granting of the final order by the Ontario Superior Court of Justice, the receipt of required regulatory approvals and the satisfaction or waiver of other customary closing conditions. The application to the Ontario Superior Court of Justice to obtain the final order approving the Arrangement is scheduled for October 17, 2016. If court approval is obtained and the other conditions to the completion of the Arrangement are satisfied or waived, Cynapsus expects that the Arrangement will be completed on or about October 21, 2016.Beneficial Securityholders are not required to take any action in respect of the completion of the Arrangement. The cash to be paid to beneficial Securityholders following completion of the Arrangement is expected to be credited to the beneficial Securityholders' broker, trustee, financial institution, dealer, bank, trust company, custodian, nominee or other intermediary account through the procedures in place for such purposes between CDS and such intermediaries. Beneficial Securityholders should contact their intermediary if they have any questions regarding this process. In order for a registered Securityholder to receive the cash consideration for the common shares or warrants following completion of the Arrangement, he, she or it must complete, sign, date and return the letter of transmittal, in accordance with the instructions set out therein that was mailed to all registered Securityholders in connection with the Meeting.

  • 13

    Oct

CYNA Cynapsus Therapeutics
$40.45

0.05 (0.12%)

07/19/16
JANY
07/19/16
NO CHANGE
Target $24
JANY
Buy
Cynapsus Phase 3 DTP results bode well for study, says Janney Capital
Janney Capital analyst Ken Trbovich believes the open-label dose titration phase, or DTP, results reported by Cynapsus Therapeutics support his expectation that the Phase 3 trial will likely result in a clinically and statistically significant difference from placebo during the randomized portion of the study. The analyst keeps a Buy rating and $24 fair value estimate on Cynapsus shares.
07/20/16
BMOC
07/20/16
NO CHANGE
BMOC
Cynapsus Therapeutics price target raised to $25 from $21 at BMO Capital
BMO Capital increased its price target on Cynapsus citing its belief that the company's APL drug will be approved in Europe. The firm keeps an Outperform rating on the shares.
08/16/16
BMOC
08/16/16
NO CHANGE
BMOC
Cynapsus Therapeutics price target raised to $30 from $25 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Cynapsus after the Data and Safety Monitoring Board, or DSMB, said that patients participating in a trial of the company's APL at-home titration product could use it at home. The analyst thinks that at-home titration appeals to doctors, and he says that the DSMB's recommendation highlights the superior safety and tolerability of the product versus injectable Apokyn. The analyst keeps an Outperform rating on Cynapsus.
09/01/16
JANY
09/01/16
DOWNGRADE
Target $40.5
JANY
Neutral
Cynapsus Therapeutics downgraded to Neutral from Buy at Janney Capital
Janney Capital analyst Ken Trbovich downgraded Cynapsus Therapeutics to Neutral citing the company's takeover by Sunovion Pharmaceuticals. The analyst has a $40.50 price target for the shares.

TODAY'S FREE FLY STORIES

KNDI

Kandi Technologies

$3.80

-0.075 (-1.94%)

09:22
04/24/17
04/24
09:22
04/24/17
09:22
Hot Stocks
Kandi Technologies announces receipt of third 2016 subsidy payment for EV sales »

Kandi Technologies Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNX

Knight Transportation

, SWFT

Swift Transportation

09:21
04/24/17
04/24
09:21
04/24/17
09:21
Upgrade
Knight Transportation, Swift Transportation rating change  »

Knight Transportation…

KNX

Knight Transportation

SWFT

Swift Transportation

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

WING

Wingstop

$28.27

0.175 (0.62%)

09:21
04/24/17
04/24
09:21
04/24/17
09:21
Upgrade
Wingstop rating change  »

Wingstop upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 20

    Jun

TRNO

Terreno Realty

09:21
04/24/17
04/24
09:21
04/24/17
09:21
Hot Stocks
Terreno Realty acquires North Bergen, New Jersey building for $14M »

Terreno Realty acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEI

Heico

09:20
04/24/17
04/24
09:20
04/24/17
09:20
Recommendations
Heico analyst commentary  »

Heico price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPLD

Upland Software

$17.07

0.16 (0.95%)

09:19
04/24/17
04/24
09:19
04/24/17
09:19
Earnings
Upland Software raises FY17 revenue view to $87.0M-$91.0M, consensus $84.18M »

Upland announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:19
04/24/17
04/24
09:19
04/24/17
09:19
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton sees Q2 North…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

$11.48

-3.15 (-21.53%)

09:19
04/24/17
04/24
09:19
04/24/17
09:19
Options
Overnight activity included 387 trades in SPX and 61 trades in VIX »

387 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

$11.48

-3.15 (-21.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHKP

Check Point

$103.41

0.77 (0.75%)

09:18
04/24/17
04/24
09:18
04/24/17
09:18
Recommendations
Check Point analyst commentary  »

Check Point price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 12

    Jun

TWTR

Twitter

09:17
04/24/17
04/24
09:17
04/24/17
09:17
Recommendations
Twitter analyst commentary  »

Twitter can beat Q1 but…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPLD

Upland Software

$17.07

0.16 (0.95%)

09:17
04/24/17
04/24
09:17
04/24/17
09:17
Hot Stocks
Upland Software acquires RightAnswers »

Upland Software announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$96.03

0.02 (0.02%)

09:16
04/24/17
04/24
09:16
04/24/17
09:16
Hot Stocks
Hasbro says has 'right brands, right team' to drive blueprint »

Regarding any potential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 18

    May

  • 31

    May

ADI

Analog Devices

$77.63

-1.03 (-1.31%)

, LLTC

Linear Technology

09:15
04/24/17
04/24
09:15
04/24/17
09:15
Upgrade
Analog Devices, Linear Technology rating change  »

Analog Devices upgraded…

ADI

Analog Devices

$77.63

-1.03 (-1.31%)

LLTC

Linear Technology

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HAL

Halliburton

09:12
04/24/17
04/24
09:12
04/24/17
09:12
Hot Stocks
Halliburton says momentum building in North America »

Says believes a bottom…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

GM

General Motors

09:12
04/24/17
04/24
09:12
04/24/17
09:12
Recommendations
General Motors analyst commentary  »

General Motors Q1 likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

HAL

Halliburton

09:11
04/24/17
04/24
09:11
04/24/17
09:11
Hot Stocks
Halliburton says seeing customers deferring new projects »

Says customers more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

ALKS

Alkermes

$56.57

-0.16 (-0.28%)

, ACOR

Acorda Therapeutics

$15.85

-0.1 (-0.63%)

09:10
04/24/17
04/24
09:10
04/24/17
09:10
Recommendations
Alkermes, Acorda Therapeutics analyst commentary  »

Alkermes 2019 earnings…

ALKS

Alkermes

$56.57

-0.16 (-0.28%)

ACOR

Acorda Therapeutics

$15.85

-0.1 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 27

    Apr

  • 27

    Apr

  • 03

    May

  • 06

    Jun

  • 08

    Jun

WTKWY

Wolters Kluwer

$41.04

-0.83 (-1.98%)

09:09
04/24/17
04/24
09:09
04/24/17
09:09
Hot Stocks
Wolters Kluwer to explore strategic alternatives for Corsearch »

Wolters Kluwer announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$47.06

-0.63 (-1.32%)

09:09
04/24/17
04/24
09:09
04/24/17
09:09
Hot Stocks
Halliburton says not chasing market share at cost of pricing »

Says seeing sufficient…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

  • 01

    May

  • 17

    May

GOGO

Gogo

$12.34

0.49 (4.14%)

09:09
04/24/17
04/24
09:09
04/24/17
09:09
Hot Stocks
Gogo signs new capacity deal with SES »

SES announced that Gogo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

GLD

SPDR Gold Trust

$122.31

0.35 (0.29%)

, SLV

iShares Silver Trust

$17.02

-0.04 (-0.23%)

09:08
04/24/17
04/24
09:08
04/24/17
09:08
Technical Analysis
Indexes and Sectors breakout above pivot highs and lows »

The major index ETFs,…

GLD

SPDR Gold Trust

$122.31

0.35 (0.29%)

SLV

iShares Silver Trust

$17.02

-0.04 (-0.23%)

TLT

iShares 20+ Year Treasury Bond Fund

XLF

Financial Select Sector

$23.16

-0.24 (-1.03%)

SPY

SPDR S&P 500 ETF Trust

$234.59

-0.75 (-0.32%)

DIA

Diamonds Fund ETF

$205.25

-0.26 (-0.13%)

IWM

iShares Trust Russell 2000 Index Fund

$137.21

-0.31 (-0.23%)

XLV

Health Care Select Sector SPDR

$73.68

-0.44 (-0.59%)

XLE

Energy Select Sector SPDR

$67.79

-0.34 (-0.50%)

XLK

Technology Select Sector SPDR

$53.17

-0.11 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGNX

Progenics

$7.75

-0.38 (-4.67%)

09:08
04/24/17
04/24
09:08
04/24/17
09:08
Recommendations
Progenics analyst commentary  »

Needham remains a buyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ADMS

Adamas Pharmaceuticals

$15.57

-0.05 (-0.32%)

09:08
04/24/17
04/24
09:08
04/24/17
09:08
Hot Stocks
Adamas: ADS-5012 data confirms reduction in levodopa-induced dyskinesia »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 24

    Aug

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

09:07
04/24/17
04/24
09:07
04/24/17
09:07
Hot Stocks
Amazon launches self-service marketplace for subscription providers »

Amazon.com announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 16

    May

  • 23

    May

HRS

Harris

$110.27

0.32 (0.29%)

09:06
04/24/17
04/24
09:06
04/24/17
09:06
Hot Stocks
Harris awarded 5-year, $875M ceiling multi-award IDIQ contract by USAF »

Harris has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.